1 active not recruiting, 1 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Terminated 1 |
Follow Multiple Sclerosis (MS): new trials by email Literature Review of Multiple Sclerosis (MS) trials Research Report on Multiple Sclerosis (MS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis Fingolimod, Ofatumumab, Siponimod - Multiple Sclerosis (MS) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 129 | 2021-10-05 | 2026-05-14 |
| Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis Nabiximols, Placebo - Multiple Sclerosis (MS) | Phase 3 | Terminated | Jazz Pharmaceuticals | 139 | 2020-10-01 | 2024-05-08 |
Multiple Sclerosis (2) · Muscle Spasticity (1) · Recurrence (1)
Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (2) · Demyelinating Autoimmune Diseases, CNS (2) · Demyelinating Diseases (2) · Immune System Diseases (2) · Nervous System Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Disease Attributes (1) · Muscle Hypertonia (1) · Muscular Diseases (1) · Musculoskeletal Diseases (1) · Neurologic Manifestations (1) · Neuromuscular Manifestations (1) · Pathologic Processes (1) · Signs and Symptoms (1)
Fingolimod Hydrochloride (1) · nabiximols (1) · ofatumumab (1) · siponimod (1)
Jazz Pharmaceuticals (1) · Novartis Pharmaceuticals (1)
Poland (2) · United States (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · Croatia (1) · Czechia (1) · Estonia (1) · France (1) · Germany (1) · Guatemala (1)
2019 (1)